Zydus Lifesciences Ltd.

Financial

	Zydus Lifesciences	Dr. Reddy's Lab	Mankind Pharma
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	486.0 .	362.0 .	67.0 .
Number of ANDA's Approved By USFDA	421.0 .	292.0 .	48.0 .
Domestic Sales Growth - YoY	6.7 %	9.1 %	7.9 %
US DMF Filings	147.0 .	n/a	n/a
R&D as a % of Total Sales	8.1 %	7.3 %	2.2 %
Financials
5 yr Average ROE	18.47 %	15.68 %	20.33 %
5yr average Equity Multiplier	1.52	1.41	1.46
5yr Average Asset Turnover Ratio	0.66	0.74	0.81
5yr Avg Net Profit Margin	19.02 %	15.18 %	17.68 %
Price to Book	4.07	3.16	7.39
P/E	21.57	18.67	55.99
5yr Avg Cash Conversion Cycle	-84.89 Days	74.48 Days	-13.08 Days
Inventory Days	36.38 Days	76.14 Days	59.06 Days
Days Receivable	36.93 Days	95.44 Days	34.35 Days
Days Payable	160.15 Days	102.6 Days	121.69 Days
5yr Average Interest Coverage Ratio	30.19	35.66	46.07
5yr Avg ROCE	19.65 %	21.82 %	25.06 %
5yr Avg Operating Profit Margin	24.4 %	23.61 %	24.62 %
5 yr average Debt to Equity	0.17	0.12	0.16
5yr CAGR Net Profit	16.23 %	23.71 %	9.49 %
5yr Average Return on Assets	12.22 %	11.24 %	14.46 %
Shareholdings
Promoter Holding	74.99 %	26.64 %	72.68 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.11 %	-0.07 %	-3.82 %
Change in Mutual Fund Holding (3 Yrs)	0.94 %	-0.6 %	5.51 %

Business

	Zydus Lifesciences	Dr. Reddy's Lab	Mankind Pharma
Product Wise Break-Up	Product Wise Break-Up US Formulations 49.5 India Formulations 24.75 Wellness 13.86 EMB Formulations 8.91 Active Pharmaceutical Ingredient (API) 1.98 Alliance 0.45 Emerging Markets 0 Europe Formulatios 0 Animal Health 0 Proprietary Products 0 Global Generics 0 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 Others 0.55	Product Wise Break-Up Cardiovascular 0 US Formulations 0 Formulations 86.8 VMN 0 Alliance 0 EMB Formulations 0 Europe Formulatios 0 Gastro - Intestinal 0 Anti-infectives 0 Neuro/CNS 0 Proprietary 1.88 Pharmaceutical 11.32 Respiratory 0 Gynaecology 0 India Formulations 0 Emerging Markets 0 Urology 0 Active Pharmaceutical Ingredient (API) 0 Anti-Diabetic 0 Wellness 0 Dermatology 0 Animal Health 0 Pain/Analgesics 0	Product Wise Break-Up Cardiovascular 13.0 US Formulations 0 Global Generics 0 VMN 7.0 Alliance 0 EMB Formulations 0 Europe Formulatios 0 Gastrointestinal 11.0 Anti-infectives 16.0 Neuro/CNS 5.0 Proprietary Products 0 0 Respiratory 8.0 Gynaecology 13.0 India Formulations 0 Emerging Markets 0 Urology 5.0 Active Pharmaceutical Ingredient (API) 0 Anti-Diabetic 8.0 Wellness 0 Dermatology 5.0 Animal Health 0 Pain/Analgesics 4.0 Others 5.0
Segment Break-Up	Segment Break-Up Pharmaceuticals 86.05 OTC 13.95	-	-
Location Wise Break-Up	Location Wise Break-Up USA 44.89 India 41.0 Russia 0 Nepal 0 Sri Lanka 0 Bangladesh 0 Others 14.11	Location Wise Break-Up India 17.36 USA 48.56 Bangladesh 0 Russia 7.99 Sri Lanka 0 Nepal 0 Others 26.09	Location Wise Break-Up India 83.0 USA 0 Bangladesh 0 Russia 0 Sri Lanka 0 Nepal 0 Others 17.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 90.91 OTC 9.09 Proprietary Products 0 0 Global Generics 0	Operating Profit Break-Up Global Generics 94.76 Pharmaceuticals 0 OTC 0 Proprietary Products 3.0 Pharmaceutical Services and Active Ingredients 2.24	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 16.0 Respiratory Systems 13.0 Anti-Infective 13.0 Gastro Intestinal 9.0 Pain Management 8.0 Dermatology 6.0 Gynecology 6.0 Central Nervous System 0 Cardiovascular 0 Oncology 0 Gastrointestinal 0 Others 29.0	Therapeutic Area Break-Up Central Nervous System (CNS) 12.12 Cardiac Science 0 Cardiac Science 6.65 Respiratory Systems 0 Anti-Infective 6.48 Gastro Intestinal 0 Gynecology 0 Oncology 27.53 Gastro Intestinal 9.52 Pain Management 9.77 Dermatology 3.13 Others 24.8	-
Asset Break-Up	Asset Break-Up India 94.06 USA 2.65 United States 0 Switzerland 0 Others 3.29	Asset Break-Up India 80.24 USA 0 Switzerland 8.45 USA 2.37 Others 8.94	-

Zydus Lifesciences Ltd.

SIGN UP FOR FREE